|
Florian Schönharting, is co-founder and partner of Nordic Biotech. Mr. Schönharting is a pioneer in Biotechnology Investments and has more than 17 years of investment experience in the biotechnology and healthcare industry.
Prior to co-founding Nordic Biotech Advisors, Mr. Schönharting was directly responsible for 20+ investments ranging from seed to late stage at a Copenhagen based financial institution (BankInvest), resulting in 10+ IPOs or trade sales, including Biomarin Inc., Bavarian Nordic Research Institute, Pharmexa, Pyrosequencing, Glyko Biomedical and Profound Pharma A/S (Maxygen Inc.). Mr. Schönharting was also the initiator, architect and founder of Genmab A/S. In addition he was responsible for seedfunding Zealand Pharma A/S and 7TM Pharma A/S. Mr. Schönharting is a former board member of Acadia Pharmaceuticals Inc., Life Cycle Pharma A/S, Curalogic A/S and a current boardmember of Osteologix Inc., Forward Pharma A/S, Gastrotech Pharma A/S, Spree Pharma A/S and Entrop Pharma A/S.
Mr. Schönharting received a master's degree in business economics (finance) from the Copenhagen Business School, and was given the McKinsey & Co award for best-of-year student.
Florian Schönharting is currently member of the Board of Directors of the Danish Venture Capital Association (DVCA) and the Danish Corporate Governance Association (DCGA).
|
